ImmunoPrecise Antibodies (OTCMKTS:IPATF) Trading Down 5.8% – Should You Sell?

ImmunoPrecise Antibodies Ltd. (OTCMKTS:IPATFGet Free Report) fell 5.8% on Monday . The company traded as low as $1.30 and last traded at $1.31. 282,780 shares traded hands during mid-day trading, an increase of 1,291% from the average session volume of 20,327 shares. The stock had previously closed at $1.39.

ImmunoPrecise Antibodies Stock Down 5.8%

The firm’s 50 day moving average is $1.90 and its 200-day moving average is $1.95.

About ImmunoPrecise Antibodies

(Get Free Report)

ImmunoPrecise Antibodies Ltd (OTCMKTS:IPATF) is a Canada-based contract research organization specializing in the discovery and development of therapeutic antibodies. The company provides a full suite of preclinical research services, from target validation and lead identification through to humanization and optimization. Its capabilities encompass hybridoma, phage display, single B cell sorting and next-generation sequencing platforms to accelerate antibody candidate selection and characterization.

ImmunoPrecise serves biopharmaceutical and biotechnology partners worldwide, offering customized solutions for projects in immuno-oncology, infectious diseases, autoimmunity and other therapeutic areas.

Further Reading

Receive News & Ratings for ImmunoPrecise Antibodies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ImmunoPrecise Antibodies and related companies with MarketBeat.com's FREE daily email newsletter.